2014 Form 10-K Financial Statement
#000114420415014238 Filed on March 05, 2015
Income Statement
| Concept | 2014 | 2013 Q4 | 2013 Q2 |
|---|---|---|---|
| Revenue | $31.17M | $7.426M | $8.056M |
| YoY Change | -9.63% | -30.25% | -21.26% |
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $2.383M | $1.240M | $2.400M |
| YoY Change | -72.92% | -61.61% | -44.95% |
| % of Gross Profit | |||
| Research & Development | $0.00 | $190.0K | $294.0K |
| YoY Change | -100.0% | -95.61% | -94.82% |
| % of Gross Profit | |||
| Depreciation & Amortization | $0.00 | $0.00 | $100.0K |
| YoY Change | -100.0% | -100.0% | -92.31% |
| % of Gross Profit | |||
| Operating Expenses | $2.383M | $1.430M | $3.156M |
| YoY Change | -85.41% | -81.11% | -68.41% |
| Operating Profit | $28.79M | $4.900M | |
| YoY Change | 58.54% | 1924.79% | |
| Interest Expense | $0.00 | $0.00 | $850.0K |
| YoY Change | -100.0% | -100.0% | -37.68% |
| % of Operating Profit | 0.0% | 17.35% | |
| Other Income/Expense, Net | $61.00K | $646.0K | |
| YoY Change | -96.07% | -765.98% | |
| Pretax Income | $28.85M | $5.480M | $4.799M |
| YoY Change | 59.2% | -158.74% | -789.51% |
| Income Tax | $56.00K | $0.00 | $80.00K |
| % Of Pretax Income | 0.19% | 0.0% | 1.67% |
| Net Earnings | $28.80M | $5.479M | $4.719M |
| YoY Change | 58.65% | -206.22% | -747.33% |
| Net Earnings / Revenue | 92.37% | 73.78% | 58.58% |
| Basic Earnings Per Share | $0.65 | $0.12 | $0.11 |
| Diluted Earnings Per Share | $0.65 | $0.12 | $0.09 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 44.13M shares | 43.73M shares | |
| Diluted Shares Outstanding | 44.25M shares | 55.27M shares |
Balance Sheet
| Concept | 2014 | 2013 Q4 | 2013 Q2 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $34.56M | $6.500M | $14.46M |
| YoY Change | 431.72% | -96.7% | -88.8% |
| Cash & Equivalents | $34.56M | $6.520M | $11.46M |
| Short-Term Investments | $0.00 | $0.00 | $3.001M |
| Other Short-Term Assets | $478.0K | $511.0K | $1.290M |
| YoY Change | -20.33% | -73.16% | -58.39% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | $0.00 | ||
| Other Receivables | $0.00 | ||
| Total Short-Term Assets | $35.04M | $7.121M | $15.75M |
| YoY Change | 393.52% | -96.42% | -88.09% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $0.00 | $0.00 | $902.0K |
| YoY Change | -100.0% | -93.65% | |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $0.00 | ||
| YoY Change | |||
| Total Long-Term Assets | $0.00 | $0.00 | $902.0K |
| YoY Change | -100.0% | -99.51% | |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $35.04M | $7.121M | $15.75M |
| Total Long-Term Assets | $0.00 | $0.00 | $902.0K |
| Total Assets | $35.04M | $7.121M | $16.65M |
| YoY Change | 393.52% | -96.44% | -94.75% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $181.0K | $93.00K | $596.0K |
| YoY Change | 81.0% | -88.02% | -0.67% |
| Accrued Expenses | $264.0K | $1.215M | $2.004M |
| YoY Change | -73.6% | -78.64% | -76.14% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | -100.0% | ||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $5.056M | $1.308M | $2.600M |
| YoY Change | 288.92% | -98.93% | -97.92% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $0.00 | $600.0K | |
| YoY Change | -100.0% | ||
| Total Long-Term Liabilities | $0.00 | $600.0K | $0.00 |
| YoY Change | -100.0% | -100.0% | |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $5.056M | $1.308M | $2.600M |
| Total Long-Term Liabilities | $0.00 | $600.0K | $0.00 |
| Total Liabilities | $5.437M | $1.866M | $2.600M |
| YoY Change | 186.16% | -98.47% | -97.93% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$129.7M | -$140.7M | |
| YoY Change | -12.28% | ||
| Common Stock | $135.0M | $154.8M | |
| YoY Change | -40.08% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $29.60M | $5.255M | $14.05M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $35.04M | $7.121M | $16.65M |
| YoY Change | 393.52% | -96.44% | -94.75% |
Cashflow Statement
| Concept | 2014 | 2013 Q4 | 2013 Q2 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | $28.80M | $5.479M | $4.719M |
| YoY Change | 58.65% | -206.22% | -747.33% |
| Depreciation, Depletion And Amortization | $0.00 | $0.00 | $100.0K |
| YoY Change | -100.0% | -100.0% | -92.31% |
| Cash From Operating Activities | $32.34M | $3.900M | $400.0K |
| YoY Change | 130.99% | -39.06% | -113.79% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $0.00 | $800.0K | $75.00M |
| YoY Change | -100.0% | -97.11% | 138.1% |
| Cash From Investing Activities | $0.00 | $800.0K | $75.00M |
| YoY Change | -100.0% | -97.11% | 138.1% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | -4.447M | -19.90M | -185.9M |
| YoY Change | -97.84% | -79.63% | 1107.14% |
| NET CHANGE | |||
| Cash From Operating Activities | 32.34M | 3.900M | 400.0K |
| Cash From Investing Activities | 0.000 | 800.0K | 75.00M |
| Cash From Financing Activities | -4.447M | -19.90M | -185.9M |
| Net Change In Cash | 27.89M | -15.20M | -110.5M |
| YoY Change | -139.34% | -76.1% | -937.12% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | $32.34M | $3.900M | $400.0K |
| Capital Expenditures | $0.00 | $0.00 | $0.00 |
| Free Cash Flow | $32.34M | $3.900M | $400.0K |
| YoY Change | 130.99% | -39.06% | -113.79% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2014Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
|
43000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
1537000 | USD |
| CY2013Q2 | us-gaap |
Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
|
1.60 | |
| CY2013Q4 | us-gaap |
Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
|
0.45 | |
| CY2013 | enzn |
Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensation
|
500000 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
1109000 | USD |
| CY2014 | enzn |
Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensation
|
30000 | USD |
| CY2013 | enzn |
Employee Service Share Based Compensation Tax Payments
EmployeeServiceShareBasedCompensationTaxPayments
|
300000 | USD |
| CY2014 | enzn |
Employee Service Share Based Compensation Tax Payments
EmployeeServiceShareBasedCompensationTaxPayments
|
30000 | USD |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
|
-200000 | USD |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
166000 | shares |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
|
0 | shares |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
|
121000 | shares |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
|
0 | shares |
| CY2014 | enzn |
Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Otherthan Options Adjustment Pursuant To Special Dividend
ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAdjustmentPursuantToSpecialDividend
|
0 | shares |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
45000 | shares |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
|
8.13 | |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
94435000 | USD |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0 | |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
|
8.77 | |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
|
0 | |
| CY2014 | enzn |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Adjustment Pursuant To Special Dividend Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentPursuantToSpecialDividendWeightedAverageGrantDateFairValue
|
0 | |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
|
6.33 | |
| CY2013 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
6313000 | USD |
| CY2014 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
10097000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
183000 | USD |
| CY2014 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
0 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
|
0 | USD |
| CY2014 | us-gaap |
Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
|
56000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
2000 | USD |
| CY2014 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
0 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-6526000 | USD |
| CY2014 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-10097000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
|
56198000 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
|
45221000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
25379000 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
19911000 | USD |
| CY2013Q4 | enzn |
Deferred Tax Assets Basis Difference In Fixed Assets
DeferredTaxAssetsBasisDifferenceInFixedAssets
|
3526000 | USD |
| CY2014Q4 | enzn |
Deferred Tax Assets Basis Difference In Fixed Assets
DeferredTaxAssetsBasisDifferenceInFixedAssets
|
2915000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
|
3663000 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
|
3647000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
2518000 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
2518000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax
DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax
|
1530000 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax
DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax
|
1530000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
|
0 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
|
0 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
|
84000 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
76894000 | USD |
| CY2013Q4 | us-gaap |
Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
|
0.45 | |
| CY2014Q4 | us-gaap |
Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
|
0.10 | |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
94935000 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
-76894000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
0 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
0 | USD |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.35 | pure |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
|
94400000 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
|
76900000 | USD |
| CY2014 | us-gaap |
Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
|
At December 31, 2014, the Company had federal net operating loss carryforwards of approximately $117.4 million that expire in the years 2020 through 2031 and New Jersey state net operating loss carryforwards of approximately $45.7 million that expire in the years 2029 through 2031. Moreover, the Company has federal and New Jersey capital loss carryforwards of approximately $8.9 million that expire in 2016 through 2019. The Company also has federal research and development tax credit carryforwards of approximately $16.6 million for tax reporting purposes that expire in the years 2017 through 2031. In addition, the Company has $3.3 million of state research and development tax credit carryforwards that expire in the years 2015 through 2026. | |
| CY2014 | us-gaap |
Income Tax Examination Description
IncomeTaxExaminationDescription
|
the Company concluded an examination by the U.S. Internal Revenue Service, in connection with the tax years 2010 through 2011. The result of such examination was the reduction of federal net operating loss carryforwards aggregating approximately $1.8 million. State income tax returns for the states of New Jersey and Indiana are generally subject to examination for a period of 3-4 years after filing of the respective returns. Income tax returns for Canada are generally subject to examination for a period of 3-5 years after filing of the respective return. | |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
1.24 | |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0 | |
| CY2013 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
100000 | USD |
| CY2014 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
0 | USD |
| CY2014Q3 | enzn |
Milestone Agreement Description
MilestoneAgreementDescription
|
Belrose provided written notice to Hisun asserting multiple breaches by Hisun of the Collaboration Agreement including failure to pay $450,000 of milestone payments. Belrose provided Hisun up to 60 days to cure the breaches. | |
| CY2013 | enzn |
Increase And Decrease In Accrued Dividends Payable
IncreaseAndDecreaseInAccruedDividendsPayable
|
0 | USD |
| CY2014 | enzn |
Increase And Decrease In Accrued Dividends Payable
IncreaseAndDecreaseInAccruedDividendsPayable
|
4417000 | USD |
| CY2013Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1215000 | USD |
| CY2014Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
458000 | USD |
| CY2013Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
93000 | USD |
| CY2014Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
181000 | USD |
| CY2013Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1308000 | USD |
| CY2014Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
5056000 | USD |
| CY2013Q4 | us-gaap |
Accrued Rent Noncurrent
AccruedRentNoncurrent
|
558000 | USD |
| CY2014Q4 | us-gaap |
Accrued Rent Noncurrent
AccruedRentNoncurrent
|
381000 | USD |
| CY2013Q4 | us-gaap |
Liabilities
Liabilities
|
1866000 | USD |
| CY2014Q4 | us-gaap |
Liabilities
Liabilities
|
5437000 | USD |
| CY2014 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>Use of Estimates</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U. S. requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the carrying value of property and equipment, valuation of investments, legal and contractual contingencies, research and development expenses, stock-based compensation, and income taxes. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2013Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
6520000 | USD |
| CY2013Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
511000 | USD |
| CY2014Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
478000 | USD |
| CY2013Q4 | us-gaap |
Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
|
90000 | USD |
| CY2014Q4 | us-gaap |
Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
|
0 | USD |
| CY2013Q4 | us-gaap |
Assets
Assets
|
7121000 | USD |
| CY2014Q4 | us-gaap |
Assets
Assets
|
35040000 | USD |
| CY2013Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2014Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2013Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
| CY2013 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
18122000 | USD |
| CY2013 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-28000 | USD |
| CY2014 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
28790000 | USD |
| CY2014Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
| CY2013Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
441000 | USD |
| CY2014Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
441000 | USD |
| CY2013Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
134512000 | USD |
| CY2014Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
130065000 | USD |
| CY2013Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-129698000 | USD |
| CY2014Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-100903000 | USD |
| CY2013Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
5255000 | USD |
| CY2014Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
29603000 | USD |
| CY2013Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
7121000 | USD |
| CY2014Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
35040000 | USD |
| CY2013Q3 | us-gaap |
Area Of Land
AreaOfLand
|
30000 | sqft |
| CY2013Q3 | enzn |
Monthly Fixed Rent Receivable On Sublease Year One
MonthlyFixedRentReceivableOnSubleaseYearOne
|
10417 | USD |
| CY2013Q3 | enzn |
Monthly Fixed Rent Receivable On Sublease Year Two
MonthlyFixedRentReceivableOnSubleaseYearTwo
|
15625 | USD |
| CY2013Q3 | enzn |
Monthly Fixed Rent Receivable On Sublease Year Three
MonthlyFixedRentReceivableOnSubleaseYearThree
|
20833 | USD |
| CY2013Q3 | enzn |
Monthly Fixed Rent Receivable On Sublease Year Four
MonthlyFixedRentReceivableOnSubleaseYearFour
|
26042 | USD |
| CY2013Q3 | enzn |
Monthly Fixed Rent Receivable On Sublease In Each Of Year Five To Eight
MonthlyFixedRentReceivableOnSubleaseInEachOfYearFiveToEight
|
35000 | USD |
| CY2013 | enzn |
Royalty Revenues From Sales Percentage
RoyaltyRevenuesFromSalesPercentage
|
0.87 | pure |
| CY2014 | enzn |
Royalty Revenues From Sales Percentage
RoyaltyRevenuesFromSalesPercentage
|
0.79 | pure |
| CY2013Q3 | enzn |
Sub Lease Commencement Date
SubLeaseCommencementDate
|
2013-11-14 | |
| CY2013Q3 | enzn |
Sublease Expiration Date
SubleaseExpirationDate
|
2021-07-30 | |
| CY2010Q4 | us-gaap |
Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
|
200000000 | USD |
| CY2013 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
22000 | shares |
| CY2014 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
0 | shares |
| CY2013 | us-gaap |
Other Sales Revenue Net
OtherSalesRevenueNet
|
647000 | USD |
| CY2014 | us-gaap |
Other Sales Revenue Net
OtherSalesRevenueNet
|
135000 | USD |
| CY2013 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
34493000 | USD |
| CY2014 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
31173000 | USD |
| CY2013 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2715000 | USD |
| CY2014 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
0 | USD |
| CY2013 | us-gaap |
Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
|
8843000 | USD |
| CY2014 | us-gaap |
Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
|
2383000 | USD |
| CY2013 | us-gaap |
Restructuring Charges
RestructuringCharges
|
4776000 | USD |
| CY2014 | us-gaap |
Restructuring Charges
RestructuringCharges
|
0 | USD |
| CY2013 | us-gaap |
Operating Expenses
OperatingExpenses
|
16334000 | USD |
| CY2014 | us-gaap |
Operating Expenses
OperatingExpenses
|
2383000 | USD |
| CY2013 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
18159000 | USD |
| CY2013 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
534000 | USD |
| CY2014 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
0 | USD |
| CY2013 | us-gaap |
Interest Expense
InterestExpense
|
2124000 | USD |
| CY2014 | us-gaap |
Interest Expense
InterestExpense
|
0 | USD |
| CY2013 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
1553000 | USD |
| CY2014 | us-gaap |
Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
|
61000 | USD |
| CY2013 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.38 | |
| CY2014 | us-gaap |
Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 1%"></td> <td style="WIDTH: 6%; PADDING-RIGHT: 0.8pt"> <div><b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>(3)</b></div> </td> <td style="WIDTH: 93%; PADDING-RIGHT: 0.8pt"> <div><b>Recently Adopted Accounting Pronouncements</b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In April 2014, the FASB issued ASU 2014-08, <i>Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity.</i> The update changes the requirements for reporting discontinued operations in Subtopic 205-20. A discontinued operation may include a component of an entity or a group of components of an entity, or a business. A disposal of a component of an entity or a group of components of an entity is required to be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business or a major equity method investment. Additionally, the update requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income and expenses of discontinued operations. This update is effective prospectively for reporting periods beginning after December 15, 2014 and early adoption is permitted. The Company is currently evaluating the impact adoption will have on its financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In May 2014, the FASB issued ASU 2014-09, <i>Revenue from Contracts with Customers (Topic 606)</i> . The core principle of this ASU is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU provides for one of two methods of transition: retrospective application to each prior period presented; or, recognition of the cumulative effect of retrospective application of the new standard in the period of initial application. This ASU is effective for fiscal years and interim periods beginning after December 15, 2016 and early application is not permitted. Management currently believes the adoption this ASU will not have a material impact on the Company’s operating results, financial position or cash flows.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In June 2014, the FASB issued ASU No. 2014-12, <i>Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period</i> . The issue is the result of a consensus of the FASB Emerging Issues Task Force (EITF). The amendments in this ASU require that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015 and can be either applied prospectively or retrospectively. Earlier adoption is permitted. Management currently believes the adoption this ASU will not have a material impact on the Company’s operating results, financial position or cash flows.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2014 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
61000 | USD |
| CY2014 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
28851000 | USD |
| CY2014 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
56000 | USD |
| CY2013 | us-gaap |
Net Income Loss
NetIncomeLoss
|
18150000 | USD |
| CY2014 | us-gaap |
Net Income Loss
NetIncomeLoss
|
28795000 | USD |
| CY2013 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
237000 | USD |
| CY2014 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
0 | USD |
| CY2013 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments And Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsAndTax
|
-320000 | USD |
| CY2014 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments And Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsAndTax
|
0 | USD |
| CY2013 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-83000 | USD |
| CY2014 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
0 | USD |
| CY2013 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
18067000 | USD |
| CY2014 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
28795000 | USD |
| CY2013 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.41 | |
| CY2014 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.65 | |
| CY2014 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.65 | |
| CY2013 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
43782000 | shares |
| CY2014 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
44125000 | shares |
| CY2013 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
51045000 | shares |
| CY2014 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
44245000 | shares |
| CY2013 | us-gaap |
Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
|
2.05 | |
| CY2014 | us-gaap |
Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
|
0 | |
| CY2013 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
232000 | USD |
| CY2014 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
0 | USD |
| CY2013 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
193000 | USD |
| CY2014 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
0 | USD |
| CY2013 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
-205000 | USD |
| CY2014 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
0 | USD |
| CY2013 | us-gaap |
Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
|
320000 | USD |
| CY2014 | us-gaap |
Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
|
0 | USD |
| CY2013 | enzn |
Amortization Of Purchase Premium On Marketable Securities
AmortizationOfPurchasePremiumOnMarketableSecurities
|
735000 | USD |
| CY2014 | enzn |
Amortization Of Purchase Premium On Marketable Securities
AmortizationOfPurchasePremiumOnMarketableSecurities
|
0 | USD |
| CY2013 | us-gaap |
Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
|
1554000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
14005000 | USD |
| CY2014 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
32338000 | USD |
| CY2013 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
2234000 | USD |
| CY2014 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
151000 | USD |
| CY2013 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
118894000 | USD |
| CY2014 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
0 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
121128000 | USD |
| CY2014 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
151000 | USD |
| CY2013 | us-gaap |
Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
|
89808000 | USD |
| CY2014 | us-gaap |
Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
|
4417000 | USD |
| CY2013 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
115849000 | USD |
| CY2014 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
0 | USD |
| CY2013 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
12000 | USD |
| CY2014 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
0 | USD |
| CY2013 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
283000 | USD |
| CY2014 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
30000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-205961000 | USD |
| CY2014 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-4447000 | USD |
| CY2013 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-70828000 | USD |
| CY2014 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
28042000 | USD |
| CY2012Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
77348000 | USD |
| CY2014 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2014 | dei |
Entity Registrant Name
EntityRegistrantName
|
ENZON PHARMACEUTICALS INC | |
| CY2014 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0000727510 | |
| CY2014 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2014 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2014 | |
| CY2014 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 6%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><b>(1)</b></div> </td> <td style="WIDTH: 93%; PADDING-RIGHT: 0.8pt"> <div style="CLEAR:both;CLEAR: both"><b>Description of Business</b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px 0pt 36.75pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Enzon Pharmaceuticals, Inc. (together with its subsidiaries, “Enzon” or the “Company”) receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products, namely, PegIntron <font style="FONT-SIZE: 10pt"><sup style="font-style:normal">®</sup></font>, Sylatron <font style="FONT-SIZE: 10pt"><sup style="font-style:normal"> ®</sup></font>, Macugen <font style="FONT-SIZE: 10pt"><sup style="font-style:normal">®</sup></font> and CIMZIA <font style="FONT-SIZE: 10pt"><sup style="font-style:normal"> ®</sup></font>. The Company had previously received royalty revenues from licensing arrangement related to sales of Oncaspar and Adagen until the Company’s rights to receive royalties on sales of these products expired in 2014. In addition, the Company’s rights to receive royalties on sales of Macugen and CIMZIA expired in the U.S. and Great Britain in 2014. The primary source of the Company’s royalty revenues is sales of PegIntron, which is marketed by Merck & Co., Inc. (“Merck”). The Company currently has no clinical operations and limited corporate operations. Royalty revenues from sales of PegIntron accounted for approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 79</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 87</font>% of the Company’s total royalty revenues in 2014 and 2013, respectively. <b> </b>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company was previously dedicated to the research and development of innovative therapeutics for patients with high unmet medical needs.   In December 2012, the Company announced that the Company’s Board of Directors retained Lazard Frères & Co. LLC (“Lazard”) to act as financial advisor in a review of the possible sale or disposition of one or more corporate assets or a sale of the Company and that the Company’s Board of Directors established a special committee to oversee the Company’s sale review process. In connection with the Company’s sale review process, the Company substantially suspended all clinical development activities with a goal of conserving capital and maximizing value returned to the Company’s stockholders.   In April 2013, the Company announced that it had concluded a review of the sale or disposition of one or more corporate assets, or a sale of the Company.   The review did not result in a definitive offer to acquire the Company or all or substantially all of the Company’s assets.   In the same announcement, the Company also announced that its Board of Directors intends to distribute excess cash, expected to arise from ongoing royalty revenues, in the form of periodic dividends to stockholders. </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In April 2013, pursuant to the terms of an asset purchase agreement, the Company sold to Belrose Pharma, Inc. (“Belrose”), all right, title and interest to the Company’s Customized PEGylation platform and related assets. The assets included (i) intellectual property and know-how associated with the PEGylation platform, (ii) patents and know-how related to PEG- SN-38, (iii) patents and know-how associated with certain of the Company’s internal clinical programs and (iv) certain related supplies and equipment.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In September 2013, the Company entered into a sublease agreement, which was amended and restated in November 2013, with Axcellerate Pharma, LLC (“Axcellerate”), pursuant to which the Company subleases to Axcellerate a portion of the Company’s premises consisting of approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30,000</font> rentable square feet of the building located at 20 Kingsbridge Road, Piscataway, New Jersey and a share of related parking areas. The term of the sublease commenced on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">November 14, 2013</font> and will expire on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">July 30, 2021</font>. The monthly fixed rent payable by Axcellerate to us under the sublease is as follows: (i) in year one, $ <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,417</font>, (ii) in year two, $ <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,625</font>, (iii) in year three, $ <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20,833</font>, (iv) in year four, $ <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 26,042</font> and (v) in each of years five through eight, $ <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 35,000</font>. The sublease also provides for Axcellerate to pay additional rent to cover its applicable share of real estate taxes, operating expenses, sewer and gas usage, water usage, electricity usage and certain other charges incurred by Axcellerate.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In October 2013, the Company terminated its License and Collaboration Agreement with Santaris Pharma A/S (“Santaris”) whereby Enzon returned to Santaris the rights to molecules utilizing LNA technology including the mRNA antagonists targeting Hypoxia-Inducible Factor-1 alpha (HIF-1 alpha), the Androgen Receptor (AR), HER3, and Beta-catenin.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company has no intention of resuming any clinical development activities or acquiring new sources of royalty revenues.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2014 | dei |
Document Type
DocumentType
|
10-K | |
| CY2014 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2014 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2014-12-31 | |
| CY2014 | enzn |
Redemptions From Employee Stock Purchase Plan
RedemptionsFromEmployeeStockPurchasePlan
|
0 | USD |
| CY2013 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | USD |
| CY2014 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | USD |
| CY2013 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-1334000 | USD |
| CY2014 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-33000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
-683000 | USD |
| CY2014 | us-gaap |
Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
|
88000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
-3877000 | USD |
| CY2014 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2014 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2014 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2014 | dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | |
| CY2014Q2 | dei |
Entity Public Float
EntityPublicFloat
|
45195458 | USD |
| CY2014 | dei |
Trading Symbol
TradingSymbol
|
ENZN | |
| CY2015Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
44182102 | shares |
| CY2013Q4 | us-gaap |
Dividends Payable Current
DividendsPayableCurrent
|
0 | USD |
| CY2014Q4 | us-gaap |
Dividends Payable Current
DividendsPayableCurrent
|
4417000 | USD |
| CY2012Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
77468000 | USD |
| CY2013 | us-gaap |
Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
|
-484000 | USD |
| CY2014 | us-gaap |
Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
|
-30000 | USD |
| CY2013 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
12000 | USD |
| CY2013 | us-gaap |
Dividends Common Stock Stock
DividendsCommonStockStock
|
89808000 | USD |
| CY2014 | us-gaap |
Dividends Common Stock Stock
DividendsCommonStockStock
|
0 | USD |
| CY2013 | enzn |
Redemptions From Employee Stock Purchase Plan
RedemptionsFromEmployeeStockPurchasePlan
|
33000 | USD |
| CY2014 | us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
-934000 | USD |
| CY2014 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
55500 | USD |
| CY2014 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>Concentrations of Risk</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">At December 31, 2014 and 2013, the Company had invested none of its cash in financial instruments, nor does it anticipate holding such instruments in the future. In prior periods, holdings of financial instruments, were comprised, principally, of money market funds and debt securities.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2013 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
186000 | USD |
| CY2013Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
85000 | USD |
| CY2014Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
5000 | USD |
| CY2013Q4 | us-gaap |
Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent
|
332000 | USD |
| CY2014Q4 | us-gaap |
Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent
|
0 | USD |
| CY2013Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
150000 | USD |
| CY2014Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
88000 | USD |
| CY2013Q4 | enzn |
Accrued Legal Current
AccruedLegalCurrent
|
160000 | USD |
| CY2014Q4 | enzn |
Accrued Legal Current
AccruedLegalCurrent
|
0 | USD |
| CY2013Q4 | us-gaap |
Accrued Rent Current
AccruedRentCurrent
|
239000 | USD |
| CY2014Q4 | us-gaap |
Accrued Rent Current
AccruedRentCurrent
|
171000 | USD |
| CY2013Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
249000 | USD |
| CY2014Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
194000 | USD |
| CY2014 | enzn |
Right Expiry Date
RightExpiryDate
|
2012-05-16 | |
| enzn |
Stock Repurchased And Retired During Period Average Price Paid Per Share
StockRepurchasedAndRetiredDuringPeriodAveragePricePaidPerShare
|
9.48 | ||
| us-gaap |
Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
|
16174578 | shares | |
| us-gaap |
Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
|
153400000 | USD | |
| CY2013Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
|
1998000 | USD |
| CY2013Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
4920000 | USD |
| CY2013Q4 | us-gaap |
Future Minimum Sublease Rentals Sale Leaseback Transactions Within One Year
FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear
|
193000 | USD |
| CY2013Q4 | us-gaap |
Future Minimum Sublease Rentals Sale Leaseback Transactions Within Two Years
FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears
|
258000 | USD |
| CY2013Q4 | us-gaap |
Future Minimum Sublease Rentals Sale Leaseback Transactions Within Three Years
FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears
|
356000 | USD |
| CY2013Q4 | us-gaap |
Future Minimum Sublease Rentals Sale Leaseback Transactions Within Four Years
FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears
|
420000 | USD |
| CY2013Q4 | us-gaap |
Future Minimum Sublease Rentals Sale Leaseback Transactions Thereafter
FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter
|
1085000 | USD |
| CY2013Q4 | us-gaap |
Future Minimum Sublease Rentals Sale Leaseback Transactions
FutureMinimumSubleaseRentalsSaleLeasebackTransactions
|
2312000 | USD |
| CY2014Q4 | us-gaap |
Area Of Land
AreaOfLand
|
30000 | sqft |
| CY2014Q4 | enzn |
Monthly Fixed Rent Receivable On Sublease Year One
MonthlyFixedRentReceivableOnSubleaseYearOne
|
10417 | USD |
| CY2014Q4 | enzn |
Monthly Fixed Rent Receivable On Sublease Year Two
MonthlyFixedRentReceivableOnSubleaseYearTwo
|
15625 | USD |
| CY2014Q4 | enzn |
Monthly Fixed Rent Receivable On Sublease Year Three
MonthlyFixedRentReceivableOnSubleaseYearThree
|
20833 | USD |
| CY2014Q4 | enzn |
Monthly Fixed Rent Receivable On Sublease Year Four
MonthlyFixedRentReceivableOnSubleaseYearFour
|
26042 | USD |
| CY2014 | us-gaap |
Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
|
0.06 | pure |
| CY2013 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
56000 | USD |
| CY2014 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
0 | USD |
| CY2014 | us-gaap |
Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
|
0.5 | pure |
| CY2013Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
703000 | USD |
| CY2013Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
703000 | USD |
| CY2013Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
742000 | USD |
| CY2013Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
774000 | USD |
| CY2014Q4 | enzn |
Monthly Fixed Rent Receivable On Sublease In Each Of Year Five To Eight
MonthlyFixedRentReceivableOnSubleaseInEachOfYearFiveToEight
|
35000 | USD |
| CY2014 | enzn |
Sub Lease Commencement Date
SubLeaseCommencementDate
|
2013-11-14 | |
| CY2014 | enzn |
Sublease Expiration Date
SubleaseExpirationDate
|
2021-07-30 | |
| CY2011Q4 | enzn |
Milestone Payment
MilestonePayment
|
5000000 | USD |
| enzn |
Acquisiton Of Inprocess Research And Development And Mile Stone Payment Under License Agreement
AcquisitonOfInprocessResearchAndDevelopmentAndMileStonePaymentUnderLicenseAgreement
|
34000000 | USD | |
| CY2011 | enzn |
Royalties Persuant To Provision In Sales Agreement
RoyaltiesPersuantToProvisionInSalesAgreement
|
500000 | USD |
| CY2007Q3 | enzn |
Percentage Of Royalty Payable Sold Under Merck Agreement
PercentageOfRoyaltyPayableSoldUnderMerckAgreement
|
0.25 | pure |
| CY2011Q4 | enzn |
Uncertain Milestone Payment
UncertainMilestonePayment
|
17000000 | USD |
| CY2010 | us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
27000000 | USD |
| CY2013 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
-30000 | USD |
| CY2014 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
0 | USD |
| CY2013 | enzn |
Current State And Foreign Tax Expense Benefit
CurrentStateAndForeignTaxExpenseBenefit
|
2000 | USD |
| CY2014 | enzn |
Current State And Foreign Tax Expense Benefit
CurrentStateAndForeignTaxExpenseBenefit
|
56000 | USD |
| CY2013 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
-28000 | USD |
| CY2014 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
56000 | USD |
| CY2013 | enzn |
Deferred Federal And State Income Tax Expense Benefit
DeferredFederalAndStateIncomeTaxExpenseBenefit
|
0 | USD |
| CY2014 | enzn |
Deferred Federal And State Income Tax Expense Benefit
DeferredFederalAndStateIncomeTaxExpenseBenefit
|
0 | USD |
| CY2013Q2 | us-gaap |
Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
|
1.60 | |
| CY2013Q4 | us-gaap |
Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
|
0.45 | |
| CY2014Q4 | us-gaap |
Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
|
0.10 | |
| CY2013 | enzn |
Separation Cost
SeparationCost
|
4800000 | USD |
| CY2014 | enzn |
Separation Cost
SeparationCost
|
0 | USD |
| CY2013 | enzn |
Benefits Provided To Existing Employees On Accural Utilization
BenefitsProvidedToExistingEmployeesOnAccuralUtilization
|
32000 | USD |
| CY2014 | enzn |
Benefits Provided To Existing Employees On Accural Utilization
BenefitsProvidedToExistingEmployeesOnAccuralUtilization
|
4000000 | USD |
| CY2014 | us-gaap |
Restructuring Reserve Accrual Adjustment
RestructuringReserveAccrualAdjustment
|
0 | USD |
| CY2014Q4 | us-gaap |
Restructuring Reserve
RestructuringReserve
|
268000 | USD |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
6.90 | |
| CY2014 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2012Q4 | us-gaap |
Restructuring Reserve
RestructuringReserve
|
777000 | USD |
| CY2013Q4 | us-gaap |
Restructuring Reserve
RestructuringReserve
|
905000 | USD |
| CY2013 | us-gaap |
Payments For Restructuring
PaymentsForRestructuring
|
4648000 | USD |
| CY2014 | us-gaap |
Payments For Restructuring
PaymentsForRestructuring
|
555000 | USD |
| CY2013 | enzn |
Restructuring Reserve Expense Or Adjustment
RestructuringReserveExpenseOrAdjustment
|
-167000 | USD |
| CY2014 | enzn |
Restructuring Reserve Expense Or Adjustment
RestructuringReserveExpenseOrAdjustment
|
-82000 | USD |
| CY2013 | us-gaap |
Restructuring Reserve Accrual Adjustment
RestructuringReserveAccrualAdjustment
|
4943000 | USD |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
0 | shares |
| CY2014 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | shares |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
519000 | shares |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
470000 | shares |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
4.08 | |
| CY2013Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.2634 | pure |
| CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
pure | |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
pure | |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
pure | |
| CY2013Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6M | |
| CY2014Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
||
| CY2013Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
||
| CY2014Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
||
| CY2013Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0015 | pure |
| CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
pure | |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
pure | |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
pure | |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2125000 | shares |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
519000 | shares |
| CY2014 | enzn |
Employee Stock Purchase Plan Description
EmployeeStockPurchasePlanDescription
|
The 2007 Employee Stock Purchase Plan (ESPP) permits eligible employees to purchase common stock through payroll deductions which may not exceed 15 percent of the employee’s compensation, as defined, at a price equal to 85 percent of the fair market value of the shares at the beginning of the offering period (grant date) or at the end of the offering period (purchase date), whichever is lower. All benefit-eligible employees of the Company may participate in the ESPP other than those who own shares or hold options or nonvested shares representing a combined 5 percent or more of the voting power of the Company’s outstanding stock. The ESPP was terminated on April 1, 2013. | |
| CY2014 | enzn |
Employee Stock Purchase Plan Termination Income
EmployeeStockPurchasePlanTerminationIncome
|
4000 | USD |
| CY2014 | enzn |
Payment To Employee Stock Purchase Plan Termination
PaymentToEmployeeStockPurchasePlanTermination
|
14000 | USD |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
7.64 | |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
-1606000 | shares |
| CY2014 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
4.08 | |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
4.51 | |
| CY2014 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P2Y6M11D | |
| CY2014 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P2Y6M11D | |
| CY2014 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P2Y3M4D | |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
0 | USD |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
0 | USD |
| CY2014Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
0 | USD |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.343 | pure |
| CY2013 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P4Y | |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.008 | pure |
| CY2013 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
4000 | USD |
| CY2014 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
0 | USD |
